Boston Scientific Corporation $BSX Holdings Lifted by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd boosted its position in Boston Scientific Corporation (NYSE:BSX) by 148.8% during the second quarter, Holdings Channel.com reports. The fund owned 1,120,331 shares of the medical equipment provider’s stock after purchasing an additional 670,060 shares during the quarter. Boston Scientific accounts for 0.9% of Y Intercept Hong Kong Ltd’s holdings, making the stock its 4th largest holding. Y Intercept Hong Kong Ltd’s holdings in Boston Scientific were worth $47,816,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the company. FWL Investment Management LLC acquired a new position in shares of Boston Scientific in the 2nd quarter valued at about $26,000. Swiss RE Ltd. acquired a new stake in Boston Scientific during the 4th quarter worth approximately $26,000. Garton & Associates Financial Advisors LLC purchased a new position in Boston Scientific in the fourth quarter valued at approximately $26,000. Clal Insurance Enterprises Holdings Ltd purchased a new position in Boston Scientific in the first quarter valued at approximately $28,000. Finally, Sfam LLC acquired a new position in Boston Scientific during the fourth quarter valued at approximately $29,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Piper Sandler reissued an “overweight” rating and issued a $65.00 price objective on shares of Boston Scientific in a research report on Friday, June 12th. Royal Bank Of Canada reduced their target price on shares of Boston Scientific from $85.00 to $70.00 and set an “outperform” rating on the stock in a report on Thursday, July 30th. Truist Financial decreased their price target on shares of Boston Scientific from $62.00 to $57.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Mizuho lowered their price target on Boston Scientific from $90.00 to $70.00 and set an “outperform” rating for the company in a report on Wednesday, July 15th. Finally, Needham & Company LLC cut their price objective on Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a research report on Wednesday, July 8th. Twenty-four research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Boston Scientific has a consensus rating of “Moderate Buy” and a consensus target price of $71.62.

Boston Scientific Price Performance

Shares of BSX stock opened at $51.40 on Thursday. The firm has a fifty day simple moving average of $45.94 and a 200-day simple moving average of $59.69. The company has a market capitalization of $74.49 billion, a PE ratio of 20.81, a price-to-earnings-growth ratio of 1.12 and a beta of 0.56. Boston Scientific Corporation has a twelve month low of $42.20 and a twelve month high of $109.50. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter in the previous year, the firm posted $0.75 EPS. The firm’s quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities research analysts anticipate that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific declared that its Board of Directors has authorized a stock buyback program on Monday, May 18th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s board of directors believes its shares are undervalued.

Insiders Place Their Bets

In other Boston Scientific news, Director Cheryl Pegus acquired 1,770 shares of the stock in a transaction on Wednesday, May 20th. The stock was purchased at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the purchase, the director directly owned 1,770 shares in the company, valued at $99,987.30. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director David C. Habiger acquired 2,100 shares of the company’s stock in a transaction on Wednesday, August 5th. The shares were acquired at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the acquisition, the director directly owned 17,160 shares in the company, valued at $816,644.40. The trade was a 13.94% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought 204,322 shares of company stock worth $9,939,221 in the last quarter. Company insiders own 0.34% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.